Marizomib

Drug Profile

Marizomib

Alternative Names: MRZ; NPI-0052; Salinosporamide A

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer Celgene Corporation; Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Lactones; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Glioblastoma
  • Preclinical Cancer
  • No development reported Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 27 Jul 2017 European Organisation for Research and Treatment of Cance and Celgene plan a pivotal phase III trial in Glioblastoma (First-line therapy, Adjunctive therapy, Newly-diagnosed) in April 2018 (NCT03345095)
  • 18 Nov 2016 Updated efficacy and adverse events data from a phase I/II trial in Glioblastoma released by Triphase Accelerator Corporation
  • 17 Nov 2016 Celgene Corporation acquires marizomib from Triphase Accelerator Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top